Price T Rowe Associates Inc Blueprint Medicines Corp Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,464,968 shares of BPMC stock, worth $190 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,464,968
Previous 5,415,837
72.95%
Holding current value
$190 Million
Previous $479 Million
60.83%
% of portfolio
0.02%
Previous 0.06%
Shares
19 transactions
Others Institutions Holding BPMC
# of Institutions
400Shares Held
67.3MCall Options Held
973KPut Options Held
1.54M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
Jpmorgan Chase & CO New York, NY2.51MShares$324 Million0.02% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...